Thu. 25 Apr 2024, 6:31am ET
Benzinga
Earnings, Earnings Beats, Earnings Misses, News
Sage Therapeutics (NASDAQ:SAGE) reported quarterly losses of $(1.80) per share which missed the analyst consensus estimate of $(1.65) by 9.09 percent. The company reported quarterly sales of $7.902 million which beat the analyst consensus estimate of $5.658 million by 39.65 percent. This is a 139.89 percent increase over sales of $3.294 million the same period last year.